Skip to Content

Citracal Calcium Pearls (calcium / vitamin d) Disease Interactions

There are 10 disease interactions with Citracal Calcium Pearls (calcium / vitamin d):

Major

Calcium Salts (Includes Citracal Calcium Pearls) ↔ Calcium- Phosphate Calcifications

Severe Potential Hazard, High plausibility

Applies to: Phosphate Imbalance

Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. These complexes are eliminated in the feces. Clinical monitoring of serum calcium and phosphate concentrations is necessary.

References

  1. "Product Information. Posture (calcium phosphate, triphasic)." Whitehall-Robbins, Madison, NJ.
  2. "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Major

Calcium Salts (Includes Citracal Calcium Pearls) ↔ Cardiac Contraction/Conduction

Severe Potential Hazard, High plausibility

Applies to: Arrhythmias

Calcium is involved in cardiac muscle contraction and electrical impulse conduction. Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease. Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias. Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.

References

  1. "Product Information. Posture (calcium phosphate, triphasic)." Whitehall-Robbins, Madison, NJ.
  2. "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Major

Calcium Salts (Includes Citracal Calcium Pearls) ↔ Malabsorption

Severe Potential Hazard, High plausibility

Applies to: Achlorhydria, Malabsorption Syndrome

Calcium is absorbed from the intestinal tract by active transport and passive diffusion. Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium. Calcium is available in oral and parenteral formulations.

References

  1. "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. "Product Information. Posture (calcium phosphate, triphasic)." Whitehall-Robbins, Madison, NJ.
Major

Calcium Salts (Includes Citracal Calcium Pearls) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment. Hyperphosphatemia occurs during renal failure. Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure. Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.

References

  1. "Product Information. Posture (calcium phosphate, triphasic)." Whitehall-Robbins, Madison, NJ.
  2. "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Major

Calcium Salts (Includes Citracal Calcium Pearls) ↔ Sarcoidosis

Severe Potential Hazard, High plausibility

Applies to: Sarcoidosis

Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis. Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma. Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.

References

  1. "Product Information. Posture (calcium phosphate, triphasic)." Whitehall-Robbins, Madison, NJ.
  2. "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  3. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
Major

Vitamin D Analogs (Includes Citracal Calcium Pearls) ↔ Arrhythmia

Severe Potential Hazard, High plausibility

Applies to: Arrhythmias

Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
  2. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
  3. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
Major

Vitamin D Analogs (Includes Citracal Calcium Pearls) ↔ Electrolyte Imbalance

Severe Potential Hazard, High plausibility

Applies to: Phosphate Imbalance

Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
  2. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
  3. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
  4. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical, Abbott Park, IL.
View all 4 references
Major

Vitamin D Analogs (Includes Citracal Calcium Pearls) ↔ Hypercalcemia

Severe Potential Hazard, Moderate plausibility

Applies to: Hypercalcemia, Malabsorption Syndrome

Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.

Major

Vitamin D Analogs (Includes Citracal Calcium Pearls) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.

References

  1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.
  2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
  3. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
Moderate

Vitamin D Analogs (Includes Citracal Calcium Pearls) ↔ Hepatobiliary Dysfunction

Moderate Potential Hazard, High plausibility

Applies to: Biliary Obstruction, Liver Disease

Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.

References

  1. "Product Information. Calderol (calcifediol)." Organon, West Orange, NJ.
  2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
  3. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma, Mequon, WI.

Citracal Calcium Pearls (calcium / vitamin d) drug Interactions

There are 439 drug interactions with Citracal Calcium Pearls (calcium / vitamin d)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide